Calamos Advisors LLC Has $7.95 Million Stock Holdings in CME Group Inc. (NASDAQ:CME)

Calamos Advisors LLC lessened its stake in shares of CME Group Inc. (NASDAQ:CME) by 3.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,452 shares of the financial services provider’s stock after selling 1,477 shares during the period. Calamos Advisors LLC’s holdings in CME Group were worth $7,953,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Gold Investment Management Ltd. bought a new stake in shares of CME Group in the fourth quarter valued at approximately $26,000. Salomon & Ludwin LLC bought a new stake in shares of CME Group in the first quarter valued at approximately $28,000. Northwest Financial Advisors bought a new stake in shares of CME Group in the fourth quarter valued at approximately $28,000. Rise Advisors LLC bought a new stake in shares of CME Group in the first quarter valued at approximately $41,000. Finally, McClarren Financial Advisors Inc. boosted its position in shares of CME Group by 89.5% in the first quarter. McClarren Financial Advisors Inc. now owns 216 shares of the financial services provider’s stock valued at $47,000 after acquiring an additional 102 shares during the period. Institutional investors and hedge funds own 87.75% of the company’s stock.

CME Group Price Performance

Shares of NASDAQ CME traded down $2.57 during midday trading on Friday, reaching $207.05. 1,273,912 shares of the company traded hands, compared to its average volume of 1,924,431. The firm has a market cap of $74.55 billion, a PE ratio of 23.56, a PEG ratio of 6.27 and a beta of 0.52. The stock’s 50-day simple moving average is $199.69 and its 200-day simple moving average is $207.19. CME Group Inc. has a 12 month low of $190.70 and a 12 month high of $223.80. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.01 and a current ratio of 1.02.

CME Group (NASDAQ:CME) last issued its quarterly earnings data on Wednesday, July 24th. The financial services provider reported $2.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.03. CME Group had a return on equity of 12.82% and a net margin of 56.98%. The company had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.53 billion. During the same period last year, the business earned $2.30 earnings per share. The business’s revenue was up 12.7% on a year-over-year basis. As a group, equities analysts anticipate that CME Group Inc. will post 9.8 earnings per share for the current fiscal year.

CME Group Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 25th. Stockholders of record on Monday, September 9th will be paid a $1.15 dividend. The ex-dividend date of this dividend is Monday, September 9th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.22%. CME Group’s dividend payout ratio (DPR) is presently 52.33%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CME. JPMorgan Chase & Co. increased their price objective on CME Group from $187.00 to $191.00 and gave the company an “underweight” rating in a research report on Thursday, July 25th. Barclays raised their target price on CME Group from $208.00 to $209.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft raised their target price on CME Group from $193.00 to $200.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Keefe, Bruyette & Woods raised their target price on CME Group from $212.00 to $213.00 and gave the stock a “market perform” rating in a research report on Thursday, July 25th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $225.00 target price on shares of CME Group in a research report on Tuesday, August 20th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $213.27.

Insider Activity

In other news, Director Daniel R. Glickman sold 650 shares of the firm’s stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $201.44, for a total value of $130,936.00. Following the completion of the sale, the director now directly owns 14,008 shares in the company, valued at $2,821,771.52. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Daniel R. Glickman sold 650 shares of CME Group stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $201.44, for a total value of $130,936.00. Following the completion of the sale, the director now directly owns 14,008 shares in the company, valued at $2,821,771.52. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Charles P. Carey sold 3,000 shares of CME Group stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $195.44, for a total value of $586,320.00. Following the completion of the sale, the director now owns 7,163 shares of the company’s stock, valued at $1,399,936.72. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by corporate insiders.

CME Group Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.